Documentation Page

ORIGINAL ARTICLE

Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study

This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue.

L Hodson1,5, L Bhatia2,5, E Scorletti2,3, DE Smith2,3, NC Jackson4, F Shojaee-Moradie4, M Umpleby4, PC Calder2,3 and CD Byrne2,3

BACKGROUND/OBJECTIVE: Treatment of subjects with non-alcoholic fatty liver disease (NAFLD) with omega-3 polyunsaturated fatty acids (FAs) suggests high levels of docosahexaenoic acid (DHA) tissue enrichment decrease liver fat content. We assessed whether changes in erythrocyte DHA enrichment (as a surrogate marker of changes in tissue enrichment) were associated with alterations in hepatic de novo lipogenesis (DNL), postprandial FA partitioning and hepatic and peripheral insulin sensitivity in a sub-study of the WELCOME trial (Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD (non-alcoholic fatty liver disease) with OMacor thErapy).

SUBJECTS/METHODS: Sixteen participants were randomised to 4 g/day EPA+DHA (n = 8) or placebo (n = 8) for 15–18 months and underwent pre- and post-intervention measurements. Fasting and postprandial hepatic FA metabolism was assessed using metabolic substrates labelled with stable-isotope tracers (2H2O and [U-13C]palmitate). Insulin sensitivity was measured by a stepped hyperinsulinaemic-euglycaemic clamp using deuterated glucose. Participants were stratified according to change in DHA erythrocyte enrichment (< or ≥ 2% post intervention).

RESULTS: Nine participants were stratified to DHA ≥ 2% (eight randomised to EPA+DHA and one to placebo) and seven to the DHA < 2% group (all placebo). Compared with individuals with erythrocyte < 2% change in DHA abundance, those with ≥ 2% enrichment had significant improvements in hepatic insulin sensitivity, reduced fasting and postprandial plasma triglyceride concentrations, decreased fasting hepatic DNL, as well as greater appearance of 13C from dietary fat into plasma 3-hydroxybutyrate (all P < 0.05).

CONCLUSIONS: The findings from our pilot study indicate that individuals who achieved a change in erythrocyte DHA enrichment ≥ 2% show favourable changes in hepatic FA metabolism and insulin sensitivity, which may contribute to decreasing hepatic fat content.

European Journal of Clinical Nutrition (2017) 71, 973–979; doi:10.1038/ejcn.2017.9; published online 15 March 2017

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver fat-related conditions that increase risk of chronic metabolic disease such as type 2 diabetes and cardiovascular disease, with obesity and insulin resistance (IR) being well-documented risk factors.1 IR appears to be a key mediator in the initiation and progression of NAFLD, mainly through adverse changes in glucose, fatty acid (FA) and lipoprotein metabolism;2 liver fat content appears to be the best independent predictor of peripheral and hepatic IR.3 A net retention of triglyceride (TG) within the liver is a prerequisite for the development of NAFLD and increased FA flux to the liver, increased FA synthesis within the liver, and decreased hepatic FA oxidation have all been implicated in NAFLD development.4,5

High-dose omega-3 FA (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) are a licensed treatment to reduce plasma TG concentrations.5 As NAFLD is associated with an overproduction of very low-density lipoprotein (VLDL)-TG,6 it is plausible that one contributor to the hypotriglycerideremic effect of omega-3 FA is through a lowering of liver fat content. We7 and others8,9 have reported that omega-3 FA have the potential to decrease liver fat. In addition to potentially lowering liver fat, short-term omega-3 FA treatment has been reported to improve whole-body insulin sensitivity.8,9 However, the effects of omega-3 FA on insulin sensitivity in the context of NAFLD remains unclear, as some studies report neutral or negative results,10,11 despite a concomitant reduction in NAFLD severity.12

The current study is a pre-specified sub-study of the WELCOME* randomised double-blind, placebo-controlled trial.7,13 The aim of this pilot sub-study was to test if a pre-specified increase (≥ 2%) in erythrocyte enrichment of DHA7,13 was associated with changes in hepatic FA synthesis, postprandial FA partitioning and hepatic and peripheral insulin sensitivity.

MATERIALS AND METHODS

Twenty-four individuals recruited from the main trial were randomly allocated to the sub-study (n = 12 randomised to EPA+DHA, 4 g/day and

---

1Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), Radcliffe Department of Medicine, University of Oxford, Oxford, UK; 2Human Development and Health Academic Unit, Southampton, UK; 3NHIR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, UK and Diabetes and Metabolic Medicine, Department of Nutritional Sciences, University of Surrey, Guildford, UK. Correspondence: Dr L Hodson, Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), Radcliffe Department of Medicine, University of Oxford, Churchill Hospital, Headington, Oxford OX3 7LE, UK. E-mail: leanne.hodson@ocdem.ox.ac.uk

5These authors contributed equally to this work.

Received 15 September 2016; revised 13 January 2017; accepted 17 January 2017; published online 15 March 2017
Participants allocated to placebo (n=12) between baseline and end of the study. All seven subjects in the sub-study. The latter had a 4.2% increase in erythrocyte DHA enrichment (DHA ≥ 2%) between baseline and end of the study. Four patients with diabetes were not included in the analysis as their anti-diabetic regimens increased between baseline and end-of-study tests. Similarly, one participant who lost >10 kg in weight over the course of the trial was also excluded. We compared participants who showed an increase in erythrocyte DHA enrichment of 2% or greater (DHA ≥ 2%) between baseline and end of the study with participants showing little change in erythrocyte DHA enrichment (DHA < 2%). In the DHA ≥ 2% group eight participants had been randomised to EPA+DHA intervention and one participant had been randomised to placebo; the latter had a 4.2% increase in erythrocyte DHA between baseline and end of the study. All seven subjects in the DHA < 2% group had been randomised to placebo.

Experimental procedures
Blood samples were taken after an overnight fast (12 h) and serum separated within 1 h to undergo routine biochemical assay. Blood pressure was measured using a Marquette DASH 3000 monitor (GE Healthcare, Bucks, UK), body composition by dual-energy X-ray absorptiometry and liver fat content measured at baseline and end of the study by magnetic resonance spectroscopy. We also measured a validated index of hepatic insulin sensitivity by dividing the basal endogenous glucose production rates by the fasting insulin concentration.20

Red blood cell FA composition
To determine specific FA composition erythrocyte ghosts were prepared, membranes isolated, total lipids isolated, FA methyl esters prepared and FA compositions determined by gas chromatography (GC), as described elsewhere.13

Assessment of whole-body and hepatic insulin sensitivity
Insulin sensitivity was measured using a two-step hyperinsulinaemic-euglycaemic clamp with a deuterated glucose (6,6-2H2 glucose) infusion3,16 to assess hepatic and peripheral insulin sensitivity. Briefly, subjects arrived at the NIHR Wellcome Trust Clinical Research Facility after an overnight (12 h) fast and intravenous cannulae were placed in both antecubital veins for sampling and infusion of labelled glucose and insulin during the two-step hyperinsulinaemic-euglycaemic clamp.15,16 Glucose isotopic enrichment was determined from deproteinised plasma using the methoxime-trimethylsilyl ether derivative, which was measured by GC mass spectrometry using selected ion monitoring.15 A modified version of the equations formulated by Steele et al.17 for non-steady state was used to calculate total rate of appearance (Ra) of glucose, endogenous glucose production (at basal and low-dose insulin stage) and rate of disappearance (Rd) as well as metabolic clearance rate (at the high-dose insulin stage) of glucose adjusted to fat-free mass μmol/kg/min. For the Steele equations, 65% was used as the effective fraction and 0.22 l/kg as the distribution volume of glucose to calculate Ra and Rd.17,18 Plasma glucose and tracer to tracee ratio time courses were smoothed using optimal segment smoothing method.21 We also measured a validated index of hepatic insulin sensitivity by dividing the basal endogenous glucose production rates by the fasting insulin concentration.20

Fasting hepatic DNL and postprandial hepatic FA partitioning
Approximately 2 weeks after the assessment of whole-body and hepatic insulin sensitivity, subjects underwent a postprandial study day as previously described. Briefly, to assess fasting hepatic de novo

Figure 1. Consort diagram showing recruitment for the WELCOME sub-study and the numbers of subjects available for hepatic fatty acid metabolism and insulin sensitivity studies. See text for the reasons for withdrawal from the study.

n=12 randomised to placebo (olive oil, 4 g/day; see Figure 1).12,13 The duration of intervention was 15–18 months and inclusion and exclusion criteria were described previously.13 For the main trial patients were randomised according to standardised procedures (computerised block randomisation in blocks of four, either to trial medication or placebo were used) by a research pharmacist at University Hospital Southampton NHS Foundation Trust.13 This randomisation strategy was maintained for the sub-study. The study was approved by the South Hampshire Local Research Ethics Committee (REC 08/H0502/165). All subjects gave written informed consent for both the main trial and the sub-study. Three participants withdrew from the sub-study before completing all tests. Four patients with diabetes were not included in the analysis as their anti-diabetic regimens increased between baseline and end-of-study tests, which would have influenced change in insulin sensitivity measurements. Similarly, one participant who lost >10 kg in weight over the course of the trial was also excluded. We compared participants who showed an increase in erythrocyte DHA enrichment of 2% or greater (DHA ≥ 2%) between baseline and end of the study with participants showing little change in erythrocyte DHA enrichment (DHA < 2%). In the DHA ≥ 2% group eight participants had been randomised to EPA+DHA intervention and one participant had been randomised to placebo; the latter had a 4.2% increase in erythrocyte DHA between baseline and end of the study. All seven subjects in the DHA < 2% group had been randomised to the placebo.
lipogenesis (DNL), subjects consumed deuterated water \(^{2}D_{2}O; 3 \text{ g/kg body water}\) the evening before the study day to achieve a body water enrichment of 0.3%. Subjects arrived at the Clinical Research Facility after an overnight fast and were fed a standard test meal that contained 200 mg of \[^{13}C\]palmitic acid (isotope purity 97%, CK Gas Products Ltd, Hook, UK) to trace the fate of dietary FA. Serial blood and breath samples were taken throughout the 5 h postprandial period.

Biochemical analysis

Whole blood was collected into heparinized syringes (Starstedt, Leicester, UK) and plasma was rapidly separated for the measurement of metabolite and insulin concentrations. Separations of chylomicrons of Svedberg flotation rate \(S_{f}>400\) and VLDL-rich fraction \(S_{f} 20–400\) were made by sequential flotation using density gradient ultracentrifugation and the \(S_{f} 20–400\) fraction was then further separated by immunoaffinity chromatography.

FA analysis and isotopic enrichment

To determine specific FA composition and isotopic enrichment, total lipids were extracted from plasma and lipoproteins and FA methyl esters were prepared. FA compositions in these fractions were determined by GC, and palmitate concentrations were calculated as described elsewhere. \(^{13}C/^{12}C\) ratios in plasma non-esteriﬁed fatty acid, \(S_{f} 400\) and VLDL-rich fraction \(S_{f} 20–400\) were measured using a Delta Plus XP GC-combustion-isotope ratio MS (GC-C-IRMS) (Thermo Electron Corporation, Bremen, Germany) and \(^{13}C\) concentrations calculated as previously described.

To assess ketone body production arising from the oxidation of dietary \[^{13}C\]palmitate, we measured isotopic enrichment of \(^{13}C\) in plasma 30HB. Fasting hepatic DNL was assessed based on the incorporation of deuterium from \(^{2}D_{2}O\) in plasma water (Finnigan GasBench-II, ThermoFisher Scientific, Hemel Hempstead, UK) into VLDL-TG palmitate using GC mass spectrometry. The concentration of VLDL-TG derived from DNL was determined by multiplying %DNL and the concentration of TG in VLDL.

Sample size, calculations and statistical analysis

The sample size for the main study was powered to detect a change in liver fat content, as described previously. The sub-study reported here was run as a hypothesis-generating pilot study. Analyses under the curve were calculated by the trapezoid method and were divided by the relevant period to give a time-averaged value. Data were analysed using SPSS for Windows v20 (SPSS, Chertsey, UK). Statistical significance was set at \(P < 0.05\). Data are reported as mean (s.e.m) unless otherwise stated. All data sets were tested for normality according to the Shapiro–Wilk test. Baseline results were compared with end of study results using a paired t-test or the Wilcoxon signed rank test for non-parametric data. Comparisons between the two groups were undertaken using independent t-test or Mann–Whitney U-test for non-parametric data.

### RESULTS

**Subject characteristics**

Baseline and end of study characteristics of participants with a change in erythrocyte DHA enrichment of \(\geq 2\%\) \((n = 9)\) or \(< 2\%\) \((n = 7)\) are shown in Table 1. One participant randomised to the placebo group had a significant increase in erythrocyte EPA and DHA enrichment \((0.8 \text{ and } 4.2\%\), respectively) between baseline and end of study measurements; the increase is most likely because they started consuming more oily fish or over-the-counter fish oil capsules during the course of the trial. There was no significant change in body mass index or body fat percentage between baseline and end of study in either group (Table 1). Baseline liver fat content ranged from 5.3 to 85% and although liver fat decreased to a greater extent in the DHA \(\geq 2\%\) group, this difference did not reach statistical significance.

We measured erythrocyte FA composition as a surrogate marker for tissue, specifically liver, FA enrichment. The DHA \(\geq 2\%\) group had a significant \((P < 0.001)\) change in the erythrocyte enrichment of EPA \((by \geq 300\%)\) and DHA \((by 92\%)\) between baseline and end of study measurements; there was no change in the DHA \(< 2\%\) group (Table 1).

There was no difference between baseline and end of study in the fasting plasma concentrations of glucose, insulin, non-esteriﬁed fatty acid, total, low-density lipoprotein cholesterol or high-density lipoprotein cholesterol (Table 2). Fasting plasma TG and VLDL-TG concentrations were signiﬁcantly \((P < 0.001)\) decreased by 0.6 mmol/l and 0.7 mmol/l, respectively, in the DHA \(\geq 2\%\) group, while concentrations remained unchanged in the DHA \(< 2\%\) group (Table 2).

We measured the incorporation of newly synthesised palmitate (DNL) into VLDL-TG in the fasting state and found no difference in the relative contribution between baseline and end of study in either group (Table 2). However, when expressed as the absolute concentration of VLDL-TG derived from DNL there was a significant \((P < 0.05)\) decrease in the DHA \(\geq 2\%\) group between baseline and end of study measurements but there was no change in the DHA \(< 2\%\) group (Table 2).

| Variables | \(DHA \geq 2\%\) \((n = 9)\) | \(DHA < 2\%\) \((n = 7)\) |
|-----------|-----------------|-----------------|
| Group (treatment/placebo) | 8/1 | 0/7 |
| Sex (M/F) | 5/4 | 6/1 |
| Age (year) | 45.7 ± 4.4 | 56.7 ± 2.5 |
| Weight (kg) | 94.9 ± 5.4 | 98.3 ± 1.6 | 95.9 ± 2.6 |
| BMI (kg/m²) | 33.3 ± 1.2 | 33.4 ± 0.9 | 32.8 ± 1.3 | 31.8 ± 0.8 |
| Waist circumference (cm) | 110.8 ± 2.9 | 110.9 ± 2.9 | 111.8 ± 1.6 | 109.6 ± 1.2 |
| DEXA % body fat | 40.0 ± 2.1 | 39.8 ± 2.2 | 33.8 ± 3.3 | 34.8 ± 2.6 |
| MRS liver fat (%) | 34.4 ± 8.5 | 25.3 ± 6.1 | 18.9 ± 5.4 | 15.9 ± 12.3 |
| MRI visceral mass (kg) | 3.36 ± 0.43 | 3.53 ± 0.32 | 3.79 ± 0.34 | 3.41 ± 0.19 |
| MAP (mmHg) | 102.7 ± 3.6 | 99.4 ± 3.4 | 104.2 ± 4.8 | 102.9 ± 4.2 |
| HDL Ch (mg/dl) | 58.0 ± 0.1 | 58.0 ± 0.2 | 60.0 ± 0.2 | 59.0 ± 0.3 |
| Erythrocyte EPA (%) | 6.0 ± 0.13 | 3.44 ± 0.47* | 1.00 ± 0.10 | 0.90 ± 0.08* |
| Erythrocyte DHA (%) | 3.68 ± 0.60 | 7.08 ± 0.47* | 4.62 ± 0.40 | 4.81 ± 0.26 |

Abbreviations: Abbreviations: BMI, body mass index; DEXA, dual-energy X-ray absorptiometry; DHA, docosahexaenoic acid; End, end of study; EPA, eicosapentaenoic acid; HDL Ch, glycated haemoglobin A1c; MAP, mean arterial pressure; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy. Data presented as mean ± s.e.m. *\(P < 0.001\) between baseline and end of study measurements within the respective groups.

European Journal of Clinical Nutrition (2017) 973–979
We observed a significant \( P < 0.05 \) decrease in the appearance of \( [U^{13C}] \) palmitate in the plasma non-esterified fatty acid pool in the DHA < 2% group, but not in the DHA ≥ 2% group (Table 2). There was a significant \( P < 0.01 \) decrease in the appearance of \( [U^{13C}] \) palmitate in VLDL-TG and a significant \( P < 0.01 \) increase in the incorporation of \( ^{13}C \) into plasma 3OHB in the DHA ≥ 2% group whilst the DHA < 2% group remained unchanged (Table 2).

Whole-body insulin sensitivity (M-value) and peripheral glucose disposal (Rd) during the high-dose insulin stage did not change in the DHA ≥ 2% group but not the DHA < 2% group (Table 2). There was a significant \( P < 0.01 \) increase in the fasting data, there was a significant \( P < 0.001 \) decrease in postprandial plasma TG and VLDL-TG concentrations between baseline and end of study measurements in the DHA ≥ 2% group but not the DHA < 2% group (Table 2). There was a significant \( P < 0.05 \) decrease in plasma 3OHB concentration over the postprandial period in the DHA ≥ 2% group (Table 2).

We included \( [U^{13C}] \) palmitate as part of the mixed test meal, to trace the fate of dietary FA over the 5 h postprandial period. We observed a significant \( P < 0.05 \) decrease in the appearance of \( [U^{13C}] \) palmitate in the plasma non-esterified fatty acid pool in the

### Abbreviations
- DHA: docosahexaenoic acid
- EGP: endogenous glucose production
- FFM: fat-free mass
- IR: insulin resistance
- M-value: glucose infusion rate
- MCR: metabolic clearance rate
- Ra: Rate of appearance of glucose
- Rd: rate of glucose disposal
- 3OHB: 3-hydroxybutyrate
- LDL: low-density lipoprotein
- HDL: high-density lipoprotein
- NEFA: non-esterified fatty acid
- TG: triglyceride
- VLDL: very low-density lipoprotein

### Table 2. Comparison between baseline and end of study blood metabolites and markers of hepatic fatty acid synthesis and partitioning in non-diabetic participants stratified by change in erythrocyte DHA enrichment (≥ 2% or < 2%)

| Variables                                             | Baseline | End | Baseline | End |
|-------------------------------------------------------|----------|-----|----------|-----|
| Glucose (mmol l⁻¹)                                     | 5.6 ± 0.2| 5.9 ± 0.3 | 5.6 ± 0.2 | 5.5 ± 0.2 |
| Insulin (μU l⁻¹)                                       | 35 ± 6   | 33 ± 8   | 40 ± 11  | 21 ± 3  |
| Total cholesterol (mmol l⁻¹)                           | 4.5 ± 0.3| 4.7 ± 0.4 | 5.1 ± 0.6| 4.6 ± 0.3 |
| HDL-cholesterol (mmol l⁻¹)                             | 1.2 (0.7, 1.4)| 1.3 (0.9, 1.4)| 1.0 (0.9, 1.2)| 1.1 (1.0, 1.1) |
| LDL-cholesterol (mmol l⁻¹)                             | 2.6 ± 0.2| 3.0 ± 0.3 | 2.5 ± 0.3 | 2.5 ± 0.4 |
| TG (mmol l⁻¹)                                          | 2.1 ± 0.3| 1.5 ± 0.2a| 2.3 ± 0.4 | 2.6 ± 0.5 |
| VLDL-TG (μmol l⁻¹)                                     | 1348 ± 212| 635 ± 88a| 1497 ± 319| 1641 ± 429 |
| NEFA (μmol l⁻¹)                                        | 550 ± 55 | 570 ± 74 | 653 ± 79 | 663 ± 80 |
| 3OHB (μmol l⁻¹)                                        | 83 ± 13  | 58 ± 15  | 93 ± 19  | 106 ± 34 |

### Time-averaged postprandial plasma concentrations

| [\(^{13C}\)]NEFA (μmol l⁻¹)                         | 0.6 ± 0.2 | 0.4 ± 0.1 | 1.0 ± 0.6 | 1.0 ± 0.6 |
| [\(^{13C}\)]VLDL-TG (μmol l⁻¹)                      | 0.22 ± 0.09| 0.20 ± 0.08| 0.16 ± 0.05| 0.07 ± 0.02b |
| [\(^{13C}\)]3OHB (μmol l⁻¹)                         | 0.1 ± 0.1  | 0.6 ± 0.2b| 0.2 ± 0.1  | 0.2 ± 0.1  |

### Abbreviations
- 3OHB: 3-hydroxybutyrate
- DHA: docosahexaenoic acid
- DNL: de novo lipogenesis
- EGP: endogenous glucose production
- FFM: fat-free mass
- HDL: high-density lipoprotein
- LDL: low-density lipoprotein
- NEFA: non-esterified fatty acid
- TG: triglyceride
- VLDL: very low-density lipoprotein

Data presented as mean ± s.e.m or median (25th, 75th percentiles).

### Table 3. Comparison between baseline and end of study markers of hepatic and whole-body insulin sensitivity in non-diabetic participants grouped by change in erythrocyte DHA enrichment (≥ 2% or < 2%)

| Variables                                             | Baseline | End | Baseline | End |
|-------------------------------------------------------|----------|-----|----------|-----|
| Basal endogenous glucose production (Ra; μmol/min/kg FFM) | 15.2 ± 0.8| 14.4 ± 0.7 | 13.4 ± 0.7 | 14.0 ± 1.0 |
| Low-dose insulin EGP (μmol/min/kg FFM)                 | 87.0 ± 9 | 78.0 ± 7 | 7.1 ± 0.5 | 6.7 ± 1.0 |
| High-dose insulin total body glucose disposal (Rd; μmol/min/kg FFM) | 35.0 ± 3.1| 34.3 ± 4.2| 30.4 ± 3.5| 35.9 ± 5.5 |
| High-dose insulin total body glucose clearance (MCR; ml/min/kg FFM) | 7.17 ± 0.84| 6.79 ± 0.75| 6.12 ± 0.73| 7.26 ± 1.16 |
| M-value (ml/min/kg)                                   | 3.22 ± 0.33| 3.21 ± 0.34| 3.23 ± 0.61| 3.77 ± 0.73 |
| Hepatic insulin sensitivity index (μmol/min/kg FFM; mU/l) × 10² | 0.54 (0.36, 0.82) | 0.63 (0.42, 0.89)b | 0.52 (0.30, 0.67) | 0.55 (0.46, 1.42) |
| Adipose-IR × 10²                                       | 75.5 ± 11.0| 109.0 ± 38.9| 110.0 ± 27.6| 67.9 ± 10.1 |

### Abbreviations
- DHA: docosahexaenoic acid
- EGP: endogenous glucose production
- FFM: fat-free mass
- IR: insulin resistance
- M-value: glucose infusion rate
- MCR: metabolic clearance rate
- Ra: Rate of appearance of glucose
- Rd: rate of glucose disposal
- 3OHB: 3-hydroxybutyrate

Data presented as mean ± s.e.m or median (25th, 75th percentiles).

\( P < 0.001 \) between baseline and end of study measurements within the respective groups.
study, with no change being observed in the DHA < 2% group (Table 3). We investigated whether a change in liver fat percentage was associated with changes in insulin sensitivity. In exploratory analyses, we stratified the cohort into two equal groups by the median change in liver fat percentage during the trial. Group 1 represented a ‘high’ reduction in liver fat (range −3% to −53%), whilst Group 2 represented minimal change or increase in liver fat (range −1.3% to +33%). When we analysed the difference in percentage suppression of endogenous glucose production at the low-dose insulin step between the groups (as another measure of hepatic insulin sensitivity), percentage suppression was significantly better in Group 1 vs Group 2 (13.7 vs −3.8% (95% confidence interval 1.4, 33.5, P < 0.05)). However, the difference in percentage increase of glucose disposal (measure of whole-body insulin sensitivity) was not significantly different (Group 1, 26.7% vs Group 2, 8.7% (95% confidence interval −56.2, 92.3, P = 0.61)).

We found an inverse association between change in erythrocyte DHA enrichment and change in fasting plasma VLDL-TG concentrations (rS = 0.59, P < 0.05; Figure 2a). We also assessed the association between change in hepatic DNL and change in erythrocyte DHA enrichment and found an inverse association (rS = −0.58, P < 0.05; Figure 2b). Lastly, we assessed the association between change in erythrocyte DHA status and the change in the incorporation of 13C from dietary fat into plasma 3OHB and found a significant positive correlation (rS = 0.74, P < 0.01; Figure 2c).

DISCUSSION
We report here data demonstrating that individuals with NAFLD, who have an increase in erythrocyte DHA enrichment of ≥2% (as a marker of tissue enrichment) through treatment with omega-3 FA, show favourable changes in both hepatic insulin sensitivity and hepatic FA metabolism. Although erythrocyte DHA enrichment ≥2% was associated with a nonsignificant (26%) decrease in liver fat content, hepatic DNL significantly decreased while hepatic FA oxidation and hepatic insulin sensitivity significantly increased. Further analysis of our data revealed a reduction in liver fat was also significantly associated with improved hepatic, but not peripheral, insulin sensitivity. Given that increased liver fat is associated with defects in insulin-mediated suppression of glucose production, our study extends this observation by showing a significant improvement in hepatic insulin sensitivity over 18 months in association with a reduction in liver fat.

Liver fat content is associated with an overproduction of VLDL, which may result in dyslipidaemia and a decrease in liver fat content may contribute to a decrease in VLDL-TG production. In line with previous work, we found a significant decrease in fasting and postprandial VLDL-TG concentrations in the DHA ≥ 2% group only. Evidence from kinetic studies has demonstrated that omega-3 FA decrease TRL particle concentrations by decreasing hepatic TRL apoB-100 synthesis and secretion rates and increasing TRL-to-low-density lipoprotein conversion. We did not measure TRL production, secretion or conversion rates in the current study.

FA availability is a determinant of VLDL-TG production. We found the absolute contribution of FA derived from hepatic DNL to VLDL-TG in the fasting state was significantly decreased in the DHA ≥ 2% group. A plausible explanation for the decrease in DNL is that omega-3 FA inhibit sterol regulatory element-binding protein 1c (SREBP1c), which leads to a downregulation in the expression of several key lipogenic genes involved in FA synthesis. We observed a significant decrease in the appearance of [13C]palmitate in VLDL-TG over the postprandial period in the DHA ≥ 2% group, with no change in the DHA < 2% group, suggesting a change in the intrahepatic partitioning of dietary FA. In support of this observation, we found a notable increase in the appearance of 13C (from dietary FA) into plasma 3OHB, suggesting intrahepatic metabolism was being moved away from esterification toward ketogenic pathways over the postprandial period. These observations are also in line with the liver becoming more insulin sensitive in the DHA ≥ 2% group.

Supplementation with EPA+DHA has been reported to decrease liver fat in some but not all studies. In the present study, individuals who increased their erythrocyte DHA enrichment by ≥2% had, on average a nonsignificant 26% decrease in liver fat content. In the WELCOME Study results, we noted some...
individuals benefitted markedly from treatment with 4 g/day DHA +EPA, while others derived no benefit; a result which cannot be explained through lack of adherence to DHA+EPA treatment.

It is important to consider the strengths and limitations of our study. Although the sample size is small in this proof of concept pilot study, we have undertaken a randomised double-blind, placebo-controlled trial testing the effects of the high-dose omega-3 FA intervention over a minimum period of 15 months. Subjects consumed either a combination of EPA+DHA or placebo (olive oil). Recent work by Allaire et al.31 reported, in a head-to-head comparison of EPA and DHA, that the latter was more effective in modulating markers of inflammation and blood lipids. It would be of interest to study the effect of a DHA treatment only against insulin resistance34 it is likely subjects in the placebo group of the current study were not supplemented with high enough doses of oleic acid to have an effect. Subjects in the placebo group consumed 4 g olive oil per day, which provided 2.4 g oleic acid per day in addition to their habitual diet; oleic acid is very prevalent in many foods of both plant and animal origin. Subjects underwent very extensive phenotyping to characterise key aspects of liver metabolism and gold-standard techniques were applied to assess liver fat, insulin sensitivity and hepatic FA partitioning. As our postprandial period was only of 5 h duration, it is plausible that we have underestimated the effects, and had we traced the meal for longer, or investigated hepatic FA partitioning after multiple meals, we may have found greater divergence between the groups. We also only measured hepatic DNL in the fasting state and it would be of interest to measure hepatic DNL in the postprandial state. Additionally, we cannot determine how early or in what order changes in liver fat, hepatic FA synthesis and partitioning, and hepatic insulin sensitivity occurred.

In conclusion, individuals with NAFLD who increase erythrocyte DHA enrichment (≥2%; as a marker for tissue enrichment) show notable changes in hepatic insulin sensitivity and hepatic FA metabolism that favour decreased hepatic DNL and increased hepatic FA oxidation which would be expected to decrease hepatic TG synthesis and storage. Variable tissue enrichment with DHA may in part, explain the differential effects of omega-3 FA treatment on hepatic fat quantity via the different pathways influenced by omega-3 FA treatment. Subjects achieving higher DHA enrichment ≥2% tended to have higher hepatic insulin sensitivity, lower fasting hepatic DNL and higher levels of hepatic fat oxidation.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**ACKNOWLEDGEMENTS**

We thank the subjects for the willingness to take part; Sandy Humphreys, Marje Gilbert and Catriona McNeil for their expert technical help; the research nurses Gillian Wise, Sanchia Triggs and Bridget Clancy; Lucinda England for her help with LREC and MHRA applications and preparing reports. The work was funded by Diabetes UK (Diabetes UK. BDA/11/0004337). NIHR Southampton Biomedical Research Centre and the British Heart Foundation (Fellowship to LH FS/17/18/28633). ES, PCC and CDB were funded in part by the Southampton NIHR Biomedical Research Centre. Clinical trials registration: NCT00765013 (2008).

**REFERENCES**

1 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Burtin EM, Cusi K et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592–1609.
2 Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27–38.
3 Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008; 134: 1369–1375.
4 Byrne CD. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet Med 2012; 29: 1098–1107.
5 McKinney JM, Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy 2007; 27: 715–728.
6 Adels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006; 49: 755–765.
7 Scorletti E, Bhatia L, McCormick CG, Clough GF, Nash K, Hodson L et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome study. Hepatology 2014; 60: 1211–1221.
8 Cussons AJ, Watts GF, Mori TA, Stuecky BG. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 2009; 94: 3842–3848.
9 Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008; 40: 194–199.
10 Galgani JE, Uauy RD, Arellano CA, Diaz EO. Effect of the dietary fat quality on insulin sensitivity. Br J Nutr 2008; 100: 471–479.
11 Janczyk W, Lebensztejn D, Wierzbicka-Rucinska A, Mazur A, Neuhoff-Murawska J, Matusik P et al. Omega-3 Fatty acids therapy in children with nonalcoholic fatty liver disease: a randomized controlled trial. J Pediatr 2015; 166: 1358–1363 e13.
12 Tanaka N, Sano K, Horuiuchi A, Tanaka E, Kiyosawa A, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 42: 413–418.
13 Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Calder PC et al. Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]. Contemp Clin Trials 2014; 37: 301–311.
14 Browning LM, Walker CG, Mander AP, West AL, Maddern J, Gambell JM et al. Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am J Clin Nutr 2012; 96: 748–758.
15 Shojaee-Moradie F, Jackson NC, Jones RH, Mallet AJ, Hovorka R, Umpleby AM. Quantitative measurement of 3-O-methyl-D-glucose by gas chromatography-mass spectrometry as a measure of glucose transport in vivo. J Mass Spectrom 1996; 31: 961–966.
16 DeFranzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1997; 237: E214–E223.
17 Steele R, Bishop JS, Dunn A, Alzuley N, Rathbøe I, Debodo RC. Inhibition by insulin of hepatic glucose production in the normal dog. Am J Physiol 1965; 208: 301–306.
18 Finegood DT, Bergman RN, Vranic M. Modeling error and apparent isotope discrimination: confusion confound estimation of endogenous glucose production during euglycemic glucose clamp. Diabetes 1998; 47: 1025–1034.
19 Finegood DT, Bergman RN. Optimal segments: a method for smoothing tracer data to calculate metabolic fluxes. Am J Physiol 1983; 244: E472–E479.
20 Matsuda M, DeFranzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462–1470.
21 Pramfalk C, Pavlides M, Banerjee R, McNeil CA, Neubauer S, Karpe F et al. Sex-specific differences in hepatic fat oxidation and synthesis may explain the higher propensity for NAFLD in men. J Clin Endocrinol Metab 2015; 100: 4425–4433.
22 Heath RB, Karpe F, Milne RW, Burdge GC, Wootton SA, Frayn K. Selective partitioning of dietary fatty acids into the VLDL TG pool in the early postprandial period. J Lipid Res 2003; 44: 2065–2072.
23 Hodson L, Bickerton AS, McQuaid SE, Roberts R, Karpe F, Frayn KN et al. The contribution of splanchic fat to VLDL triglyceride is greater in insulin-resistant than insulin-sensitive men and women: studies in the postprandial state. Diabetes 2007; 56: 2433–2441.
24 Santoro N, Caprio S, Pierpoint B, Van Name M, Savoye M, Parks EJ. Hepatic de novo lipogenesis in obese youth is modulated by a common variant in the GCKR gene. J Clin Endocrinol Metab 2015; 100: E1125–E1132.
25 Elizondo A, Araya J, Roocroft P, Polichon J, Ceredes A, Maluenda F et al. Polysaturated fatty acid pattern in liver and erythrocyte phospholipids from obese patients. Obesity (Silver Spring) 2007; 15: 24–31.
26 Elizondo A, Araya J, Rodrigo R, Signorini C, Sgherri C, Comporti M et al. Effects of weight loss on liver and erythrocyte polysaturated fatty acid pattern and

European Journal of Clinical Nutrition (2017) 973 – 979
oxidative stress status in obese patients with non-alcoholic fatty liver disease. Biol Res 2008; 41: 59–68.

27 Seppala-Lindroos A, Vehikavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023–3028.

28 Bordin P, Bodamer OA, Venkatesan S, Gray RM, Bannister PA, Halliday D. Effects of fish oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidemic males. Eur J Clin Nutr 1998; 52: 104–109.

29 Nestel PJ, Connor WE, Reardon MF, Connor S, Wong S, Boston R. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest 1984; 74: 82–89.

30 Takeuchi Y, Yahagi N, Izumida Y, Nishi M, Kubota M, Teraoka Y et al. Polyunsaturated fatty acids selectively suppress sterol regulatory element-binding protein-1 through proteolytic processing and autoloop regulatory circuit. J Biol Chem 2010; 285: 11681–11691.

31 Dasarathy S, Dasarathy J, Khiyami A, Yerian L, Hawkins C, Sargent R et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2015; 49: 137–144.

32 Scorletti E, West AL, Bhatia L, Hoile SP, McCormick KG, Burdge GC et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. J Hepatol 2015; 63: 1476–1483.

33 Allaire J, Couture P, Leclerc M, Charest A, Marin J, Lepine MC et al. A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the comparing EPA to DHA (ComparED) Study. Am J Clin Nutr 2016; 104: 280–287.

34 Perdomo L, Beneit N, Otero YF, Escibano O, Diaz-Castroverde S, Gomez-Hernandez A et al. Protective role of oleic acid against cardiovascular insulin resistance and in the early and late cellular atherosclerotic process. Cardiovasc Diabetol 2015; 14: 75.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017